ReviewBritish journal of clinical pharmacology2012
The pharmacogenetics of the response to warfarin in Chinese.
Review in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Trial
- Characteristics and Efficacy of Warfarin Sodium Tablet Subdivided by 3D Printing Technology: A Retrospective Cohort Study of Patients After Prosthetic Valve Replacement.Drug design, development and therapy · 2025Article
- Improved stacking ensemble learning based on feature selection to accurately predict warfarin dose.Frontiers in cardiovascular medicine · 2023Article
- Ethnic Diversity and Warfarin Pharmacogenomics.Frontiers in pharmacology · 2022Review
- Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations.Journal of personalized medicine · 2021Article
- Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy - A nationwide cohort study.EClinicalMedicine · 2021Article
- Variability in Human In Vitro Enzyme Kinetics.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study.Health and quality of life outcomes · 2020Article
- Delayed diagnosis of spinal subarachnoid hemorrhage in association with warfarin administration: a case report and literature review.The Journal of international medical research · 2020Review
- Heterogeneity in the distribution of 159 drug-response related SNPs in world populations and their genetic relatedness.PloS one · 2020Article
- Risk of recurrent stroke for Asian stroke patients treated with non-vitamin K antagonist oral anticoagulant and warfarin.Therapeutic advances in chronic disease · 2020Article
- The Contribution ofIranian journal of pharmaceutical research : IJPR · 2020Article
- Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.Indian heart journal · 2018Article
- Warfarin-induced life-threatening bleeding associated with a CYP3A4 loss-of-function mutation in an acute limb ischemia patient: Case report and review of the literature.Experimental and therapeutic medicine · 2017Article
- The allele frequency ofResearch in pharmaceutical sciences · 2017Article
- Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.Biomedical reports · 2016Article
- Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy.International journal of hematology-oncology and stem cell research · 2015Article
- Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?Medicine · 2015Observational
- Does ethnicity play a role in the dosing of warfarin in Hawai'i?Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2014Article
- Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?Korean circulation journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Warfarin is a commonly used oral anticoagulant with a narrow therapeutic range and large interindividual variability in daily dose. Compared with Caucasians, Chinese are known to require lower doses of warfarin. Differences between Caucasians and Chinese in the allelic frequencies of two genes, CYP2C9 and VKORC1, largely explain the difference in dose requirement. There are other genetic polymorphisms that may further explain the response to warfarin. The VKORC1 genotype is an important determinant of response to warfarin in Chinese, but some genetic variants found in other ethnic groups that have a large effect on warfarin response and dosing are not commonly found in Chinese. Therefore, it is important to recognize and beware of ethnic differences in the pharmacogenetics of the response to warfarin, especially in the design of algorithms to aid dosing in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.